GM Drug Trials Starts in UK
Scientists under the Pharma-Planta consortium in the United Kingdom (UK) used genetically engineered tobacco plants to harvest a monoclonal antibody that will stop the transmission of HIV between sexual partners. United Kingdom regulators have approved Europe's first clinical trials and this could mark the start of more trials of plant-derived medicines treating different diseases.
According to the statement released by the Consortium, "the mass production of medicines in genetically modified plants could reduce costs and therefore make an important contribution to global health, by improving access for the poor in developing countries where diseases such as HIV are a huge problem. In addition, the simple manufacturing process could be transferred to developing countries allowing production in the region for the region."
Read more information at http://www.pharma-planta.net/images/file/Pharma-Planta_Press_release_July2011.pdf.
This article is part of the Crop Biotech Update, a weekly summary of world developments in agri-biotech for developing countries, produced by the Global Knowledge Center on Crop Biotechnology, International Service for the Aquisition of Agri-Biotech Applications SEAsiaCenter (ISAAA)
View Crop Biotech Update (
July 29, 2011
) Newsletter
Subscribe to Crop Biotech Update Newsletter
Crop Biotech Update Archive
Crop Biotech Update RSS
Biofuels Supplement RSS
